



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Application of : Murray D. Bailey, et al. ) Art Unit: Not Yet Assigned  
Serial No. : 10/791,318 ) Examiner: Not Yet Assigned  
Confirmation No. : 1817  
Filed : 03/02/2004  
For : Hepatitis C Inhibitor Peptide Analogs  
Docket No. : 13/112

Commissioner For Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

July 12, 2004

**AMENDMENT AND STATEMENT UNDER 37 CFR § 1.821(f)**


Sir:

In accordance with 37 CFR 1.821(f), please amend the above-identified application by replacing the paper Sequence listing presently on file with the new paper Sequence listing submitted herewith. In accordance with 37 CFR 1.821(e), Applicants are also submitting this new Sequence Listing in computer readable form. This amendment and submission includes no new matter.

I hereby certify that:

The paper Sequence Listing and computer readable form Sequence Listing submitted herewith are identical.

Respectfully submitted,


  
Philip I. Datlow  
Attorney for Applicant(s)  
Reg. No. 41,482

Boehringer Ingelheim Corp.  
900 Ridgebury Road  
P.O. Box 368  
Ridgefield, CT. 06877  
Tel.: (203) 798-4542

I hereby certify that this correspondence is being deposited with the U.S. Postal Service as first class mail in an envelope addressed to:

Commissioner for Patents  
P. O. Box 1450  
Alexandria, VA 22313-1450

on July 12, 2004

By:   
Philip I. Datlow  
Reg. No. 41,482